OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis
Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT®...
Daiichi Sankyo Launches NaruveinⓇ Injection for Cancer Pain Treatment in Japan
Daiichi Sankyo Company, Limited announced that it has launched in Japan an injection for cancer pain treatment: NaruveinⓇ Injection 2 mg • 20 mg.
Hydromorphone...
Dupixent showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints.
In...
LYRICA Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Pfizer Inc. announced positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adjunctive therapy for...
ICON Announces Clinical Research partnership with DuPage Medical Group
ICON plc , a global provider of drug development and commercialisation solutions and services, announced that PMG Research, Inc., part of ICON Site and...
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents
Grifols , a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced the expansion of its...
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the first positive Phase 1 clinical data assessing cemiplimab as a potential treatment for advanced non-small cell...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...